Encompass Health Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders held on May 7, 2026. The filing details the voting outcomes for director elections, auditor ratification, and executive compensation approval.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a corporate governance report regarding shareholder voting.
Material Changes and Voting Results
As of the record date, there were 99,565,304 shares of common stock issued and outstanding. Votes representing 92.5% of the combined voting power were represented by proxy. All three proposals were approved:
- Proposal 1 (Election of Directors): All 10 nominees were elected. The highest "Against" vote count was 2,589,495 for Greg D. Carmichael, while the lowest was 552,777 for Mark J. Tarr.
- Proposal 2 (Auditor Ratification): Ratification of PricewaterhouseCoopers LLP passed with 88,444,873 votes for and 3,608,490 votes against.
- Proposal 3 (Executive Compensation): Approval of named executive officer compensation passed with 83,410,829 votes for and 3,006,776 votes against.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports the final vote tallies.
Key Facts for Investor Verification
- Verify the specific reasons for the "Against" votes on director nominees, particularly Greg D. Carmichael and Leslye G. Katz, which exceeded 2 million votes each.
- Confirm the total number of shares outstanding (99,565,304) against subsequent filings to check for any immediate changes in capital structure.
- Note that Proposals 1 and 3 included 5,601,574 broker non-votes each, which did not affect the outcome but indicate broker participation levels.